From Academia to Cancer Innovation

This chapter explores the speaker's transition from academia to industry in the quest for cancer drug targets, highlighting their motivation to impact patient treatment through entrepreneurial efforts. The discussion emphasizes the strategic decisions in selecting therapeutic modalities, with a focus on antibody therapeutics and the significance of antigen discovery. Additionally, it covers the importance of data infrastructure and ethical considerations in acquiring patient samples for research.